Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic
Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease…
Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic
Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease type 2C and the prevalent condition overactive bladder. This small molecule came from Actio Biosciences, which was recently acquired by Jazz Pharmaceuticals. The post Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic appeared…
MMI Raises $125M to Expand Robotic Microsurgery and Explore New Treatments
Medical Microinstruments (MMI) has raised $125 million in Series D financing to expand the reach of its Symani Surgical System and investigate new applications for microsurgery, including an experimental approach to treat Alzheimer’s disease. The post MMI Raises $125M to Expand Robotic Microsurgery and Explore New Treatments appeared first on MedCity News.
What the Midterms Mean for Healthcare and the Investors Betting on It
One question on everyone’s mind is what the impact of the midterm elections will be on the US healthcare system in the near and long term – here are 3 possible outcomes The post What the Midterms Mean for Healthcare and the Investors Betting on It appeared first on MedCity News.
Prestige Is a Business Model
An employer that treats board disclosure, community benefit reporting, and contracting terms as three separate conversations is missing that they are the same conversation. The post Prestige Is a Business Model appeared first on MedCity News.
Behavioral Health Data-Sharing Gaps Can Undermine Patient Care, Panelists Warn
Panelists urged health systems and virtual care vendors to set clear data exchange expectations
AI and Digital Tools Could Transform Clinical Trials, but Patient Involvement Remains Critical
Panelists explored external control arms and digital twins
Employer, Pharmacy Advocates Applaud DOL Final Rule on PBMs
The Department of Labor finalized a rule that seeks to bring more transparency into PBM compensation. The post Employer, Pharmacy Advocates Applaud DOL Final Rule on PBMs appeared first on MedCity News.
Implementation of Immigrant Eligibility Restrictions for ACA Marketplace Subsidies Under the 2025 Reconciliation Law: Issues to Consider
Beginning January 1, 2027, the 2025 reconciliation law will limit immigrant eligibility for ACA Marketplace subsidies. This brief provides an overview of implementation of the immigrant eligibility changes for Marketplace subsidies and issues to consider for affected individuals and states.
9 Things to Watch for the 2027 ACA Open Enrollment Period
The ACA Marketplace Open Enrollment season begins November 1, bringing higher out-of-pocket premium payments, new eligibility requirements for certain groups, and state efforts to offset premium increases following the expiration of enhanced premium tax credits. Read our analysis of what these and other changes could mean for enrollees.
Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’
Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently available monoclonal antibodies. Aspen Neuroscience also debuted on the Nasdaq as it prepares for a pivotal test of its Parkinson’s disease cell therapy. The post Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’ appeared first on…
